| Literature DB >> 29674640 |
Roddy S O'Connor1,2, Lili Guo3, Saba Ghassemi1,2, Nathaniel W Snyder4, Andrew J Worth3, Liwei Weng3, Yoonseok Kam5, Benjamin Philipson6, Sophie Trefely4, Selene Nunez-Cruz1,2, Ian A Blair3, Carl H June1,2, Michael C Milone7,8.
Abstract
Etomoxir (ETO) is a widely used small-molecule inhibitor of fatty acid oxidation (FAO) through its irreversible inhibitory effects on the carnitine palmitoyl-transferase 1a (CPT1a). We used this compound to evaluate the role of fatty acid oxidation in rapidly proliferating T cells following costimulation through the CD28 receptor. We show that ETO has a moderate effect on T cell proliferation with no observable effect on memory differentiation, but a marked effect on oxidative metabolism. We show that this oxidative metabolism is primarily dependent upon glutamine rather than FAO. Using an shRNA approach to reduce CPT1a in T cells, we further demonstrate that the inhibition of oxidative metabolism in T cells by ETO is independent of its effects on FAO at concentrations exceeding 5 μM. Concentrations of ETO above 5 μM induce acute production of ROS with associated evidence of severe oxidative stress in proliferating T cells. In aggregate, these data indicate that ETO lacks specificity for CTP1a above 5 μM, and caution should be used when employing this compound for studies in cells due to its non-specific effects on oxidative metabolism and cellular redox.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29674640 PMCID: PMC5908836 DOI: 10.1038/s41598-018-24676-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1ETO moderately inhibits T cell proliferation with minimal effect on differentiation. (A) Activated T cells (day 3) were treated with either control or 50 μM ETO every other day throughout logarithmic expansion. Live cells were enumerated using flow cytometric, bead-based approaches. The number of population doublings is plotted as a function of time. Values are means ± S.E.M. from 7 independent experiments. (*P < 0.05 for control vs ETO). (B) Representative plots (n = 6) of cell surface expression of CCR7 and CD45RO on T cells treated with 50 μM ETO for 7 days during logarithmic expansion. Cells shown have been pre-gated for live, CD3+ CD8+ T cells. (C) Relative proportion of naïve-like (CCR7+; CD45RO−), Tcm (CCR7+; CD45RO+) and Tem (CCR7−; CD45RO+) subsets (after gating on live, CD3+ CD8+ T cells). Data are plotted as mean ± S.E.M. from 6 separate donors.
Figure 2ETO inhibits oxidative glutamine metabolism in CD28-costimulated T cells. (A) Activated T cells (day 3) were switched to cell culture medium containing varying levels of glucose and glutamine. After 48 hrs, live cells were enumerated using bead-based flow cytometry, as described in the materials and methods. Representative values from two independent experiments with separate donors are shown. (B) T cells were expanded following stimulation with dynabeads. After 7 days, the cells were transferred to bicarbonate-free XF assay medium containing varying concentrations of glutamine. Metabolic parameters were measured by extracellular flux assay (Seahorse). The oxygen consumption rate (OCR) was measured at baseline and following the addition of 1.5 μM oligomycin, 1.5 μM FCCP, and 50 μM ETO. Values are means ± S.E.M. from 3 independent experiments. (C) T cells undergoing logarithmic expansion (day 7) were treated with either 10 mM 13C6 glucose or 2 mM 13C5 glutamine for 1 hr. Mass isotopomer data for acetyl-CoA are shown. Values represent means ± S.E.M. from 3 independent experiments. (D) T cells undergoing logarithmic expansion (day 7) were treated with 13C16 palmitate +/−10 μM BPTES for 2 hrs. Mass isotopomer data for acetyl-CoA are shown. Values represent means ± S.E.M. from 3 independent experiments.
Figure 3The specificity of ETO for CPT1a is lost at concentrations above 5 μM T cells expressing either control or shRNA against CPT1A were restimulated with dynabeads and expanded for 5 days. Oxygen consumption rates (OCR) in control (A) versus shRNA cells (C) under basal conditions and after the introduction of ETO (dotted lines) are shown. The corresponding glycolytic rates (ECAR) in control (B) and shRNA cells (D) cells are shown. Representative metabolic parameters from 2 independent experiments are shown. Untransduced T cells were expanded for 8 days with dynabeads and then switched to regular Seahorse assay medium (Medium) or assay medium supplemented with 1 mM sodium acetate (Acetate). Glycolytic rates were measured under basal conditions and following the introduction of 5 μM ETO (E) and 50 μM ETO (F) at the indicated time-points (dotted lines). Representative metabolic parameters from 2 independent experiments are shown.
Figure 4Commonly used concentrations of ETO induce severe oxidative stress in CD28-costimulated T cells. (A) Activated T cells were expanded in the presence of 50 μM until restdown. After thawing, these cells were processed for transmission electron microscopy. Representative images from two independent experiments are shown. Scale bars represent 500 nM. (B) ROS production in T cells treated with ETO for 4 hrs was measured by 2′,7′ dichlorofluorescein (DCF) fluorescence. Shown are the representative flow cytometry histograms (n = 5) of samples treated with either 50 μM H2O2 or 50 μM ETO. (C) Mean fluorescence intensities of cells treated with either control or ETO. (D) GSH levels of activated T cells treated with either control or 50 μM ETO over 5 days were quantified by LC-MS. Levels of reduced glutathione (Light) were assessed after normalizing to an isotopically-labeled standard (Heavy). The mean GSH levels ± SD were determined from triplicate measurements per condition in each experiment. Paired data (Ctrl vs ETO) from three individual experiments with separate donors are shown. GSH levels were decreased in ETO-treated T cells (Paired t-test analyses; *p < 0.05).